A cure concept has not yet been established for asymptomatic and untreated patients with high-risk smoldering myeloma, and debate needs to be initiated surrounding how these patients can be treated sustainably while also taking into account their age, comorbidities, fitness, personal preference, and adverse events of the therapeutic agents.
